Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Turoctocog alfa - Novo Nordisk

Drug Profile

Turoctocog alfa - Novo Nordisk

Alternative Names: N8; NN-7008; NNC-0155-0000-0004; NovoEight; Recombinant factor VIII - Novo Nordisk; rFVIII - Novo Nordisk; Zonovate

Latest Information Update: 19 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemophilia A

Most Recent Events

  • 19 Jun 2019 Novo Nordisk completes a phase III trial for Haemophilia A (In adolescents, In children, Treatment-experienced, In adults, In the elderly) in Austria, Bulgaria, France, Germany, Serbia, Turkey, United Kingdom (SC) (NCT03588741)
  • 05 Dec 2018 Novo Nordisk completes the guardian-4 phase III trial for Haemophilia A (In children, Treatment-naive) in Brazil, China, USA, Algeria, Austria, Hungary, Lithuania, Poland, Portugal, the UK, Denmark, Greece, Hong Kong, Japan, Puerto Rico, Russia, Serbia, Spain and Turkey (IV) (NCT01493778) (EudraCT2011-001033-16)
  • 11 Apr 2018 Launched for Haemophilia A (In children, In adults) in Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top